	US 12,297,469 B2
	Methods and compositions for inhibiting ADAM10 biological activities
Marcia L. Moss, Apex, NC (US); Robert Rasmussen, Lansing, NY (US); and Chris Prince, Ithaca, NY (US)
Assigned to VERRA THERAPEUTICS, INC., Lansing, NY (US)
Filed by VERRA THERAPEUTICS, INC., Lansing, NY (US)
Filed on May 19, 2022, as Appl. No. 17/748,163.
Application 17/748,163 is a continuation of application No. 16/149,764, filed on Oct. 2, 2018, abandoned.
Claims priority of provisional application 62/589,842, filed on Nov. 22, 2017.
Claims priority of provisional application 62/566,580, filed on Oct. 2, 2017.
Prior Publication US 2023/0203468 A1, Jun. 29, 2023
Int. Cl. C12N 9/64 (2006.01); A61K 38/48 (2006.01); A61K 47/60 (2017.01); A61P 37/08 (2006.01)

CPC C12N 9/6489 (2013.01) [A61K 38/4886 (2013.01); A61K 47/60 (2017.08); A61P 37/08 (2018.01)]

19 Claims

1. A peptide comprising an amino acid sequence at least 90% identical to SEQ ID NO: 62, wherein amino acid position number 29 is not arginine, amino acid position number 55 is not arginine, amino acid position number 151 is not cysteine, and amino acid position number 177 is not glutamine.